Share This Page
IODIXANOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Iodixanol, and when can generic versions of Iodixanol launch?
Iodixanol is a drug marketed by Hengrui Pharma and is included in one NDA.
The generic ingredient in IODIXANOL is iodixanol. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iodixanol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iodixanol
A generic version of IODIXANOL was approved as iodixanol by HENGRUI PHARMA on May 19th, 2022.
US Patents and Regulatory Information for IODIXANOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hengrui Pharma | IODIXANOL | iodixanol | INJECTABLE;INJECTION | 214271-001 | May 19, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hengrui Pharma | IODIXANOL | iodixanol | INJECTABLE;INJECTION | 214271-002 | May 19, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Iodixanol (Visipaque) Investment Scenario and Fundamentals Analysis
Iodixanol is an iodinated contrast media sold under the Visipaque brand and a cluster of regulated generic equivalents. The investment case depends on (1) replacement of older nonionic contrast in imaging workflows, (2) durable regulatory acceptance and formulary entrenchment, (3) supply continuity and contract pricing, and (4) exposure to procedure volumes in CT and angiography. Core patent risk is moderate because iodixanol is an established API with long-past origin claims; the value capture now sits primarily with brand/generic lifecycle management, manufacturing capacity, and regulatory dossiers rather than new primary IP.
What is iodixanol and how is it used clinically?
Iodixanol is a nonionic, dimeric, water-soluble iodinated contrast agent used to enhance visualization in diagnostic imaging. It is used in radiologic procedures including computed tomography (CT) and angiography, with positioning historically centered on tolerability compared with older ionic agents.
Key commercial relevance
- Contrast media demand is driven by imaging volumes (CT mix, outpatient growth, cardiovascular imaging).
- Product switching occurs slowly once a site or payer standardizes on a contrast formulary.
- Safety perceptions and lab experience influence procurement decisions more than theoretical performance.
Where does the product fit in the market?
Iodinated contrast is a mature, high-volume market. Iodixanol competes against other nonionic iodinated agents (e.g., iso-osmolar and low-osmolar classes) rather than within a niche therapy area.
Practical implications for valuation
- Pricing pressure comes from generic competition and channel contracting.
- Share gains track institutional adoption and tender cycles more than clinical trial differentiation.
- Demand is less tied to drug-seeking behavior and more to radiology capacity and procedure mix.
What is the IP position that matters for investment?
Iodixanol’s fundamental chemical claims and early compositions of matter are well beyond the typical commercial exclusivity horizon. For investors, the IP “edge” usually comes from one of these structures:
- Brand-specific regulatory exclusivity in certain jurisdictions (if any surviving barriers exist by filing and jurisdiction).
- Dossier control tied to manufacturing process and device-related packaging (where applicable).
- Secondary patents tied to formulations, concentration-specific presentations, or manufacturing improvements (where still active).
- Third-party generics relying on ANDA/abbreviated pathways that reduce pricing power for late entrants.
Current investment framing
- Expect the market to behave like a mature generics-and-brand industry with incremental lifecycle events, not a high-growth, long-duration primary IP platform.
How should investors model demand?
Procedure volume and mix are the demand engine
- CT utilization drives most incremental contrast spend.
- Cardiovascular and angiographic use supports a steadier base but is more sensitive to elective care cycles.
Pricing and contracting determine margin durability
- Contrast pricing is heavily tender-based.
- Generic substitution can compress realized price quickly once interchangeability or formulary preference shifts.
Supply continuity is a gating factor
- Contrast media is manufacturing- and QC-intensive with strict batch release.
- Shortages can produce temporary price lift, but repeated allocation events can trigger procurement renegotiations.
What are the key commercial KPIs for iodixanol?
For underwriting a bet on iodixanol exposure, the KPIs that consistently track outcomes are:
- US and EU market share within nonionic iodinated contrast at the institution level (tender wins).
- Net price vs. list price (contracting and rebates).
- Gross margin vs. peers (manufacturing scale, yield, and release costs).
- Manufacturing continuity (batch failure rates, lead times, FDA/EU inspection outcomes).
- Claims activity around product quality and recall history (risk of disruptions).
Investment scenario: base case, bull case, bear case
Base case (mature growth, periodic pricing pressure)
- Demand grows in line with imaging volumes and stable hospital utilization.
- Net price drifts lower as generics maintain competition.
- Margins hold through manufacturing efficiency and stable supply performance.
Likely financial shape
- Revenue grows modestly or flat in real terms.
- EBITDA margin stabilizes with cost control and contract management.
Bull case (share gains and favorable tender cycles)
- Iodixanol keeps or gains formulary positions in CT/angiography where safety perception and institutional protocols favor it.
- Tender outcomes favor the company with consistent supply and competitive net pricing.
- Any incremental regulatory or lifecycle packaging improvements support switching.
Likely financial shape
- Share gains offset generic discounting.
- Margin improves with better mix and supply reliability.
Bear case (strong generic pricing, supply events, or adverse regulatory signals)
- Aggressive generic pricing compresses net revenue.
- Any production disruption leads to allocation and procurement losses.
- Regulatory or quality-related events increase operating costs and delay shipments.
Likely financial shape
- Revenue declines or stagnates in nominal terms.
- Margin erodes due to price compression and remediation costs.
What are the primary risks and mitigants?
1) Patent and regulatory exclusivity risk (low to moderate)
- Exposure is mainly to expiration and generic entry dynamics because iodixanol is established.
- Mitigation is less about new IP and more about dossier ownership, manufacturing advantage, and formulation/packaging stability.
2) Competitive intensity (high)
- Iodixanol competes in a commoditized segment where peers can undercut with similar clinical utility.
- Mitigation is brand trust, established protocols, and the ability to win tenders on net price and supply.
3) Supply and quality risk (medium to high)
- Manufacturing issues have immediate commercial impact in contrast products.
- Mitigation comes from diversified capacity, validated processes, and conservative inventory planning.
4) Procedure-cycle risk (medium)
- Elective imaging volumes can soften with economic cycles and healthcare budget constraints.
- Mitigation is the breadth of indications and the mix of outpatient and inpatient utilization.
What signals should investors watch over the next 12 to 36 months?
- Tender pricing trends: compare contract net pricing changes versus peer nonionic iodinated agents.
- Distribution and stocking behavior: shifts in wholesaler pull-through can signal future demand or supply issues.
- Regulatory actions and quality events: warning letters, batch holds, or recall patterns.
- Manufacturing capacity announcements: expansions or risk events for API and finished-dose production lines.
- US and EU interchangeability and formulary changes: institutional switching patterns, not just brand-level sales.
Where does “alpha” realistically come from?
In iodixanol, most returns come from execution and portfolio structure rather than breakthrough science:
- Commercial execution: tender wins, contract renewal discipline, channel management.
- Manufacturing execution: yield improvements, reduced batch failures, stable supply.
- Lifecycle management: maintaining favored presentations (concentrations and pack sizes) within formularies.
- Portfolio balancing: offsetting competitive pressure in iodixanol with other contrast SKUs or adjacent imaging products.
How investors can benchmark iodixanol assets
Benchmark set
- Nonionic iodinated contrast peers: iso-osmolar and low-osmolar agents.
- Within-class pricing and margin: compare net price trends and gross margin stability across companies with similar manufacturing footprint.
What to compare (investor checklist)
- Realized net price by region
- Share by major tender aggregators or hospital networks (where data exists)
- Gross margin stability during generic entry waves
- Manufacturing capacity utilization and quality metrics
Key regulatory and safety context that supports durable adoption
Iodixanol’s market acceptance relies on clinical familiarity and safety perceptions in routine diagnostic imaging. A stable safety profile is crucial in contrast products where reimbursement and utilization depend on clinician comfort and institutional guidelines. The practical outcome for investors is steady procurement if supply remains reliable.
What’s the bottom-line investment thesis?
Iodixanol is a mature contrast product where the investment outcome is dominated by contracting economics and supply-chain execution. IP-driven upside is limited; downside is primarily pricing compression from generic competition and disruption risk. Upside comes from formulary entrenchment, tender execution, and consistent manufacturing performance.
Key Takeaways
- Iodixanol is a mature iodinated contrast agent with demand tied to CT and angiography procedure volumes and procurement cycles.
- Primary IP upside is limited; value capture depends on brand positioning, regulatory dossier control, manufacturing scale, and tender execution.
- The core underwriting drivers are net pricing, gross margin stability, supply continuity, and institution-level share.
- Investment risk concentrates in generic price erosion and operational disruptions that affect batch availability and quality.
FAQs
1) What growth drivers matter most for iodixanol?
Imaging procedure volumes, especially CT utilization, and stable hospital procurement practices.
2) Is iodixanol a patent-led investment?
No. The product sits in a mature segment where returns depend more on lifecycle management, regulatory dossier durability, and supply-chain execution than new primary IP.
3) What compresses iodixanol profitability fastest?
Generic entry and aggressive tender pricing that reduce realized net price.
4) What operational events are most likely to hurt revenue?
Manufacturing disruptions, batch release delays, and quality events that cause shipment gaps or allocation.
5) Where does competitive differentiation show up commercially?
In formulary preferences, tender outcomes, and supply reliability rather than step-change clinical performance.
References (APA)
[1] FDA. (n.d.). FDA drug shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
[2] EMA. (n.d.). European Medicines Agency (EMA) medicines. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] National Library of Medicine. (n.d.). Iodixanol (PubChem compound summary). PubChem. https://pubchem.ncbi.nlm.nih.gov/
[4] FDA. (n.d.). Drug product labeling (Drug Label Information). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
More… ↓
